Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.69 |
| ▸ | HTR1A | P08908 | 9/20 | 0.69 |
| ▸ | HTR2A | P28223 | 8/20 | 0.69 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | HRH1 | P35367 | 2/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 3/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | DRD5 | P21918 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9380224 | 0.87 | HTR1A (0.68) | DRD2HTR1AHTR2AHRH1HTR7 | |
| SCHEMBL9381653 | 0.85 | DRD2 (0.63) | DRD2HTR1AHTR2ADRD3HRH1 | |
| SCHEMBL6104465 | 0.83 | DRD2 (0.62) | DRD2HTR1AHTR2ADRD3HRH1 | |
| SCHEMBL21142444 | 0.81 | DRD2 (0.60) | DRD2HTR1AHTR2ADRD3HRH1 | |
| SCHEMBL29502326 | 0.81 | — | — | |
| SCHEMBL6185115 | 0.81 | HTR2A (0.65) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL11080954 | 0.81 | SIGMAR1 (0.59) | DRD2HTR1ADRD3SIGMAR1HTR7 | |
| SCHEMBL11080619 | 0.80 | HTR1A (0.60) | DRD2HTR1AHTR2ADRD3HRH1 | |
| Hydrochloric Acid SCHEMBL11078890 | 0.80 | SIGMAR1 (0.58) | DRD2HTR1ADRD3SIGMAR1HTR7 | |
| SCHEMBL25335774 | 0.80 | HTR2A (0.67) | DRD2HTR1AHTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | DRD2 69/4885HTR1A 13/4885HTR2A 2/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | DRD2 69/4885HTR1A 13/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.